Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.33 |
| ▸ | HTR2C | P28335 | 3/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
| ▸ | TOP2A | P11388 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PDE9A | O76083 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6156321 | 0.79 | POLB (0.38) | HTR2AHTR2CHTR2BTOP2ASMN1; SMN2 | |
| SCHEMBL1359083 | 0.78 | MAP2K1 (0.35) | HTR2AHTR2CHTR2BSMN1; SMN2 | |
| SCHEMBL19504916 | 0.77 | — | — | |
| SCHEMBL23400623 | 0.76 | HTR2A (0.41) | HTR2AHTR2CHTR2BTOP2ASMN1; SMN2 | |
| SCHEMBL6154539 | 0.76 | HTR2A (0.34) | HTR2AHTR2CHTR2BTOP2ASMN1; SMN2 | |
| SCHEMBL21502008 | 0.74 | TOP2A (0.34) | HTR2AHTR2CHTR2BTOP2ASMN1; SMN2 | |
| SCHEMBL6156758 | 0.71 | KDM4E (0.41) | SMN1; SMN2ACHE | |
| SCHEMBL6155240 | 0.71 | MAPK1 (0.45) | SMN1; SMN2ACHE | |
| SCHEMBL20197167 | 0.69 | GRM2 (0.34) | HTR2AHTR2CHTR2BGRM2 | |
| SCHEMBL691749 | 0.69 | TSHR (0.53) | HTR2AHTR2CHTR2BTOP2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4401729-A1 | BCL-XL DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| WO-2023044046-A1 | BCL-XL DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-03-23 | — | — | WO | disclosed |